Fusion Pharmaceuticals Announces Pricing of Initial Public Offering.
Hamilton, Ontario and Boston. 25 June 2020. Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. All of the shares are being offered by Fusion. …
Fusion Pharmaceuticals Announces Pricing of Initial Public Offering. Read More »